G1Flagship
The valve
Pressure-driven bladder cycling with no power and no antibiotics. Bench verified and validated in three clinical studies.
US 6,673,051World premiere · Boston · November 16, 2026
GenixUro AI resolves Catheter Associated Urinary Tract Infection (CAUTI) without antibiotics.
90.3%efficacy in preventing CAUTI in randomized Trial 1. No CAUTI in Trials 2 and 3.
A Critical Care System, built for Critical Care Medicine. A thumb-sized, sterile device that attaches to any urinary catheter and lets the bladder fill, flush and empty the way nature intended. Supported by AI diagnostics. Made in the United States.
GenixUro AI™Bladder Management System
KEYNOTE
World premiere
GenixUro AI World Premiere
- Event
- Precision in Medical Devices Summit Boston
- When
- Monday, November 16, 2026 · 9:30 AM ET
- Where
- Revere Hotel Boston Common, 200 Stuart St, Boston, MA
- Speakers
- Brian J. Awbrey, MD, FACS and Taimalelagi Rick Anderson
We are inviting you to be a guest of TekGenius, and as our guest we will get your $700 admission fee waived.
Summit runs Nov 16–17, 2026Register with a company email
Critical Care System
Built for every setting where catheters are used, from the ambulance to the home.
Emergency and transport
- Emergency Room
- EMT · Ambulatory Care
Critical care units
- Medical ICU (MICU)Manages severe internal medicine conditions, such as severe infections, diabetic ketoacidosis, poisoning and multi-organ failure.
- Operating Room & Surgical ICU (SICU)Focuses on post-operative care for patients recovering from major or high-risk surgeries.
- Cardiac / Coronary Care Unit (CCU / CICU)Dedicated to acute heart conditions such as acute coronary syndrome, myocardial infarction, heart failure and cardiogenic shock.
- Neurocritical Care Unit (NeuroICU)Specialized in severe neurological and neurosurgical emergencies like strokes, traumatic brain injuries and intracranial hemorrhages.
- Pediatric ICU (PICU) & Neonatal ICU (NICU)Tailored to the critical care needs of infants, neonates and children.
Long-term and home care
- Long Term Care
- Skilled-Nursing Facilities
- Home Health Care Monitoring
Unit descriptions: Felix Hospital, ICU types; JAMA Cardiology; JAMA Neurology.
The problem
Ninety years without a definitive solution.
Catheter Associated Urinary Tract Infection is a plumbing problem that medicine has been treating with pharmacology. Stagnant urine and biofilm shield bacteria from antibiotics and from the immune system.
1936
In Boston, Dr. Donald Munro of Harvard showed that cycling the bladder, instead of draining it constantly, cut infection at 10 days from about 73% to 15%.American Urological Association, May 19, 1936. Figures as cited in the TekGenius trial report.
“Can we build a better urinary catheter?”Calvin Kunin, New England Journal of Medicine, 1988
≈3.0MUS CAUTIs a year, every one treated with antibiotics
≈2 in 3occur in outpatient and home care, with no national surveillance
415Mindwelling catheters used worldwide each year
The device
Munro’s 1936 principle, automated.
GenixUro AI sits at the catheter outlet, upstream of the tubing and bag. The catheter doesn’t change, and the nursing workload doesn’t grow.
- OpensAt precisely 20 ± 1 cm H2O, a normal voiding pressure
- EmptiesStays open until the bladder is empty, then snaps shut, sealed against backflow
- SterileSingle-use and disposable, designed for the same maximum 30 days as the catheter
- FitsThumb-sized, and attaches to any catheter in seconds with a universal adapter
- MadeClean-room assembly in the United States
Evidence
Verified on the bench. Validated in three clinical studies.
20 ± 1cm H2O opening pressure, every cycle
100,000cycles in a separate durability run
0 refluxup to 1,400 cm H2O, 70× the opening pressure
30 / 30gelatin clot trials cleared (1 to 10 mm³)
12 devices, 180-day simulation with fresh human urine; 200 lb rolled onto the bag, tubing pinched and thrown, with no failures. Source: GenixUro AI Study Group Report, Sept 2026.
Trial 1, randomized · median 31 days on a catheter
CAUTI (NHSN definition)
Antibiotics given
Bacteriuria
- Three prospective studies in the US, Australia and Mexico, CRO-supervised and IRB-approved.
- Trial 1 was randomized, with 68 completers. CAUTI: Fisher exact p < 0.00001.
- Trials 2 and 3: 0 of 88 patients developed CAUTI and 0 of 88 needed antibiotics (prior-patient controls, supportive).
- 3,355 patient-days with no device malfunctions or safety issues reported.
- About 80% less catheter-care time in our studies.
The GenixUro AI family
A proven base device. Intelligence next.
Twenty-five years of invention and testing, taking GenixUro from a simple valve to an instrumented device to full diagnostics. Dr. Awbrey presents Generation 1 and unveils Generations 2 and 3 in Boston.
G2Unveiling Nov 16
The instrumented valve
- Sample port and over-pressure port
- RF transmit and receive
- EMF protection
- Rechargeable battery
G3Unveiling Nov 16
The diagnostic platform
- Base unit with four sterile diagnostic ports
- Modular diagnostic pods
- Clinician dashboard
Intelligence with intent and determination
- SenseUrine output and metrics
- AnalyzePressure and urine chemistry, cells, bacteria, urometrics and volumes
- InformClinician dashboard with a longitudinal AI Clinical Decision Support Agent
- Treat + DiagnoseBy cycling, plus 24/7 point-of-care monitoring
GenixUro AI treats by cycling the bladder and diagnoses both acutely and through 24/7 monitoring. Gen 3’s AI is shown here as architecture and intent; AI validation is the next chapter.
Gen 3 · Modular diagnostic pods
- Test cards6 visual test-card types covering 134 diagnostic tests, readable instantly
- Point of carePoint-of-Care diagnostic pods with 24/7 real-time urine monitoring to the EHR
- Lab on a chipChemical, biological, cell, enzyme and metabolite assays
- CollectionFour formats: microassay point-of-care, 1 mL, 5 mL and large volume
- Urometric AccessUrometric testing valve and Luer-type injection port
AI diagnostics landscape
Urine diagnostics are half a century behind.
Cardiology has continuous monitoring. Diabetes has real-time glucose. Critical care has bedside blood gases. Urine still gets a dipstick, a cup, and a culture that takes days.
1,614AI medical devices on FDA’s list
45AI lab-diagnostic authorizations
30unique devices among them
14AI devices that analyze body fluids or lab data
3urine-related AI products ever authorized
Authorized urine AI today
- Healthy.iodipstick reader
- Arkray AUTION EYEcamera imaging
- APAScamera-imaging urine culture reader
All three test a sample after it is collected.
GenixUro AI
Continuous. In line with the catheter.
None of today’s products works in line at the catheter, around the clock. GenixUro AI is built to close that gap: continuous urine analysis at the catheter, with results going straight to the care team.
Source: FDA List of AI-Enabled Medical Devices (Sept 2026 update; 1,614 records); TekGenius analysis of lab review panels. FDA notes the list is not comprehensive.
Joint venture partner · Reemetis Technologies
The AI Platform behind the device.
Reemetis Technologies brings the AI Platform to GenixUro AI: a digital nervous system and teams of cognitive assistant employees, working together as one. In Boston, Taimalelagi Rick Anderson presents the AI side of the keynote, featuring MD AutoPilot by Reemetis Technologies.
- How it worksThe digital nervous system and the cognitive assistant employees carry what GenixUro measures to the people who act on it.
- Nervous systemOne AI platform that connects every department, software system and communication channel in a medical facility.
- Cognitive assistant employeesTeams of AI cognitive assistant employees that work across the facility’s existing systems, day and night.
- PlatformMD AutoPilot by Reemetis Technologies, the VHA AutoPilot platform built for private health systems.
The team
The people behind GenixUro AI.
Dr. Brian J. Awbrey
MD, FACS · CEO, President and Chief Medical Officer
Brian Awbrey, MD, FACS, is CEO, President and Chief Medical Officer of TekGenius, where he leads the clinical research behind GenixUro AI. He gives the Boston keynote on the device, describing that evidence and the path ahead.
He continues to provide top-performing corporate leadership while advancing a broad R&D pipeline. A former surgeon-scientist with Oncology-Immunology Fellowship training at Harvard Medical School, he is twice board certified (ABMS) and spent more than 25 years as a Harvard faculty member, specialist clinician and research scientist at Massachusetts General Hospital.
Taimalelagi Rick Anderson
Chief Operations Officer and Chief R&D Engineer, TekGenius
Co-founder and Chief Operations Officer, Reemetis Technologies
Taimalelagi Rick is one of the original founding members of TekGenius, where he runs operations and research and development. As co-founder and COO of Reemetis Technologies, he leads the joint venture that brings the AI Platform to GenixUro AI: the digital nervous system and its cognitive assistant employees. In Boston he represents both companies, TekGenius and Reemetis Technologies, and presents the AI side of the keynote.
Leona Rose Rubino
RN, BSN, BA Psychology · Chief Nursing Officer
Leona is a registered nurse licensed in Florida and New York. She brings the nursing view, keeping GenixUro AI practical for the care teams who use it every day.
Michael Rawers
Chief Strategy Officer
Michael leads strategy, partnerships and the path to market, connecting GenixUro AI with the companies and health systems that will bring it to patients.
Breyon Bradford
Co-founder, Chief Executive Officer and Chief AI Architect, Reemetis Technologies
Breyon co-founded Reemetis Technologies with Taimalelagi Rick and leads the company. He designed the AI Platform behind GenixUro AI, the digital nervous system and its cognitive assistant employees, and the operating system they run on. Before Reemetis he spent two decades in enterprise engineering and systems architecture, and he leads the engineering group that builds and maintains the platform for TekGenius.
Partners · Private briefings